Targeted treatments for advanced prostate cancer

Who could benefit from this research

What this research studies

This research focuses on developing highly selective therapies for patients with high-risk localized prostate cancer, which often becomes resistant to standard hormone treatments. The approach combines local and systemic therapies, utilizing antibody-drug conjugates to enhance the effectiveness of chemotherapy while minimizing side effects. By targeting cancer cells more precisely, the goal is to improve treatment outcomes and reduce the risk of tumor recurrence. Patients may be monitored for their response to these innovative therapies over the course of the study.

Why it matters

Where this research is happening

• Case Western Reserve University
  Cleveland, United States Active

Researchers

• Principal investigator: Basilion, James Peter — Case Western Reserve University
• Study coordinator: Basilion, James Peter

Related research

Other NIH-funded projects on the same topics.

• Ariginine-depleting therapy plus chemotherapy for aggressive variant prostate cancers

  This project tests whether removing arginine from the body enhances chemotherapy for men with a difficult-to-treat prostate cancer subtype.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11391400

• Targeting master regulators to overcome AR-driven resistance in advanced prostate cancer

  This grant explores how cancer cells rewire their growth signals to resist AR-targeted therapies in advanced prostate cancer and tests new ways to block those master regulators.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11369845

• Lowering arginine with chemotherapy for aggressive prostate cancer

  Looks at whether lowering a nutrient called arginine together with platinum‑taxane chemotherapy can help men with aggressive, treatment‑resistant prostate cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11174404

• Targeting key regulators in advanced prostate cancer that resist standard treatments

  This research looks for new ways to treat advanced prostate cancer that has stopped responding to common hormone therapies.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11159586

• Investigating the impact of arginine depletion with chemotherapy in aggressive prostate cancers

  This study is looking at how lowering levels of an amino acid called arginine might make chemotherapy work better for men with aggressive prostate cancer that doesn't respond well to regular treatments.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10932183

• Targeting DNA repair pathways in prostate cancer

  This study is looking at whether a special combination of treatments can help men with non-castrate prostate cancer, especially those with certain genetic changes, by focusing on fixing DNA damage to improve their chances of recovery.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10922777

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.